YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

Analgesic Efficacy of Naproxen-Codeine, Naproxen Plus Dexamethasone, and Naproxen on Myofascial Pain: a Randomized Double-Blind Controlled Trial

dc.authorid Cigerim, Levent/0000-0001-5218-8568
dc.authorid Kaplan, Volkan/0000-0002-7605-1125
dc.authorscopusid 55318687000
dc.authorscopusid 56789733600
dc.authorwosid Kaplan, Volkan/Aba-6258-2020
dc.contributor.author Cigerim, Levent
dc.contributor.author Kaplan, Volkan
dc.date.accessioned 2025-05-10T17:09:19Z
dc.date.available 2025-05-10T17:09:19Z
dc.date.issued 2023
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp [Cigerim, Levent] Van Yuzuncu Yil Univ, Dept Oral & Maxillofacial Surg, Fac Dent, Van, Turkey; [Kaplan, Volkan] Tekirdag Namik Kemal Univ, Dept Oral & Maxillofacial Surg, Fac Dent, TR-59100 Tekirdag, Turkey en_US
dc.description Cigerim, Levent/0000-0001-5218-8568; Kaplan, Volkan/0000-0002-7605-1125 en_US
dc.description.abstract Objective To assess the effects of naproxen sodium-codeine phosphate, naproxen sodium-dexamethasone, and naproxen sodium on myofascial pain. Methods This randomized, double-blind prospective clinical study was conducted with patients who applied with the complaint of pain in the temporomandibular region. A total of 169 patients were randomly divided into four groups and received the following treatments: Group A: naproxen sodium 550 mg; Group B: naproxen sodium 550 mg + codeine phosphate 30 mg; Group C: naproxen sodium 550 mg + single-dose dexamethasone 8 mg, and Group D: paracetamol 500 mg. Results Of the patients, 132 were female, and 37 were male, with a mean age of 27.04 +/- 10.56 (18-69 years). Analgesic efficiency of the naproxen sodium-codeine phosphate group was the most effective at the 2nd week and 4th week (p< 0.05). Conclusion Naproxen sodium-codeine phosphate might be preferred as an analgesic in similar cases with severe myofascial pain. en_US
dc.description.woscitationindex Science Citation Index Expanded
dc.identifier.doi 10.1080/08869634.2020.1824411
dc.identifier.endpage 125 en_US
dc.identifier.issn 0886-9634
dc.identifier.issn 2151-0903
dc.identifier.issue 2 en_US
dc.identifier.pmid 32941116
dc.identifier.scopus 2-s2.0-85091078291
dc.identifier.scopusquality Q2
dc.identifier.startpage 119 en_US
dc.identifier.uri https://doi.org/10.1080/08869634.2020.1824411
dc.identifier.uri https://hdl.handle.net/20.500.14720/7109
dc.identifier.volume 41 en_US
dc.identifier.wos WOS:000570273800001
dc.identifier.wosquality N/A
dc.language.iso en en_US
dc.publisher Taylor & Francis Ltd en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Temporomandibular Disorders en_US
dc.subject Codeine en_US
dc.subject Naproxen en_US
dc.subject Dexamethasone en_US
dc.subject Pain en_US
dc.title Analgesic Efficacy of Naproxen-Codeine, Naproxen Plus Dexamethasone, and Naproxen on Myofascial Pain: a Randomized Double-Blind Controlled Trial en_US
dc.type Article en_US

Files